Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Pasteur reveals HIV vaccine trial results

Sanofi Pasteur reveals HIV vaccine trial results

24th September 2009

Sanofi Pasteur has unveiled the results of a trial involving a possible HIV vaccine that was conducted over six years in Thailand and involved the participation of 16,000 adult volunteers.

The study showed that the vaccine, which is produced by Sanofi Pasteur, was safe and modestly effective and the prime-boost combination of the ALVAC HIV and AIDSVAX B/E vaccines lowered the rate of HIV infection by 31.2 per cent when compared with a placebo.

A comprehensive presentation of the results is set to be conducted at the AIDS Vaccine 2009 conference in Paris on October 20th.

Michel DeWilde, senior vice-president of research and development at Sanofi Pasteur, said: “Albeit modest, the reduction of risk of HIV infection is statistically significant. This is the first concrete evidence, since the discovery of the virus in 1983, that a vaccine against HIV is eventually feasible.”

Earlier this month, Sanofi Pasteur revealed that it has submitted a supplemental application to the Food and Drug Administration for the licensure of its H1N1 monovalent vaccine.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.